v3.26.1
TAXATION (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2026
Dec. 31, 2025
Income Tax Disclosure [Abstract]    
SCHEDULE OF PROVISION FOR INCOME TAXES

The Company’s provision for income taxes for the three months ended March 31, 2026 and 2025 consisted of the following:

 

   2026   2025 
   Three months ended 
   March 31, 
   2026   2025 
         
Current tax provision  $2,099   $4,323 
Deferred tax provision   -    - 
Total provision for income taxes  $2,099   $4,323 

The Company’s income tax expenses for the years ended December 31, 2025 and 2024 are as follows. The two VIEs have no income taxes during the years ended December 31, 2025 and 2024.

 

SCHEDULE OF PROVISION FOR INCOME TAXES

   2025   2024 
   Years ended 
   December 31, 
   2025   2024 
         
Current tax provision  $4,651   $7,824 
Deferred tax provision   -    - 
Total provision for income taxes  $4,651   $7,824 
SCHEDULE OF FEDERAL STATUTORY INCOME TAX RATE

The following table reconciles the U.S. federal statutory income tax rate to the Company’s effective tax rate for the three months ended March 31, 2026 and 2025:

 

   2026($)   2026(%)  

2025 ($)

   2025(%) 
   Three months ended March 31, 
   2026($)   2026(%)  

2025 ($)

   2025(%) 
Tax provision  $31,017    21%  $(15,299)   21.00%
Effect of State taxes  $1,658    1.12%  $3,415    (4.69)%
federal effect of state tax in deferred  $1,427    0.97%  $12,785    (17.55)%
Foreign tax rate differential  $-    0.00%  $3,553    (4.88)%
R&D tax credits  $-)   0.00%  $ -)    0.00%
Change in valuation allowance  $(29,270)   (19.82)%  $1,374    (1.89)%
Credits generated in current year  $(1,181)   0.80%  $(1,507)   2.07%
FDII  $(1,054)   0.71%  $-    0.00%
Permanent differences  $-    0.00%  $2    0.00%
RTP  $-    0.00%  $-    0.00%
Federal Tax - PY  $-    0.00%  $-    0.00%
Federal Penalties  $-    0.00%  $-    0.00%
Rounding  $(499)   (0.34)%  -    0.00%
Effective tax rate  $2,099    1.42%  $4,323    (5.93)%

The following table reconciles the U.S. federal statutory income tax rate to the Company’s effective tax rate for the years ended December 31, 2025 and 2024:

 

           2025   2024 
      Years ended 
      December 31, 
   

2025 ($)

(000s)

  

2025

(%)

  

2024

(%)

 
Expected tax at 21%   $ (5,211 )   21.00%   21.00%
State and Local Taxes, Net of Federal Benefit   $ 5     (0.02)%   2.62%
Foreign Tax Effects:                  
China - Foreign rate differential   $ 0.00     0.00%   (0.26)%
Effect of Changes in Tax Laws or Rates Enacted in the Current Period   $ 0.00     0.00%   0.00%
Effect of Cross Border Tax Laws                  
FDII deduction   $ 0.00     0.00%     
Tax Credits                  
R&D Tax Credits   $ (3 )   0.01%   3.34%
Changes in Valuation Allowance   $ (153 )   0.61%   (27.06)%
Change in Warrant Valuation   $ 5,365     (21.62)%   - 
Nontaxable or Non-deductible items:                  
Penalties   $ 2     0.00%   (0.46)%
Other non-deductible expenses   $ 0.00     0.00%   0.00%
Changes in Unrecognized Tax Benefits   $ 0.00     0.00%   0.00%
Other Adjustments:                  
Impact of Annual ETR and Q4 loss impact   $ 0.00     0.00%   0.00%
Effective tax rate   $ 5     0.02%   (0.71)%
SCHEDULE OF COMPONENTS OF DEFERRED TAX ASSETS

As of March 31, 2026 and December 31, 2025, the Company had no net deferred tax assets due to a full valuation allowance recorded against its deferred tax assets. The components of deferred tax assets and liabilities were as follows:

 

   March 31,   December 31, 
   2026   2025 
         
Deferred tax asset attributable to:          
Tax effect of net operating losses carried forward  $277,994   $290,635 
Section 174 costs, net   49,891    66,522 
Warranty liabilities   9,673    9,295 
Inventory reserve   67,431    67,431 
Tax credits   66,912    66,716 
State tax   (19,562)   (18,793)
Lease Liability   13,312    27,784 
Right of Use Asset   (12,266)   (25,543)
FIN 48   1,392    - 
Deferred tax assets   454,777    484,047 
Less: valuation allowance   (454,777)   (484,047)
Deferred tax assets, net  $-   $- 

The components of deferred tax assets are as follows:

 

   2025   2024 
   December 31,   December 31, 
   2025   2024 
         
Deferred tax asset attributable to:          
Tax effect of net operating losses carried forward  $290,635   $127,579 
Section 174 costs, net (1)   66,522    125,323 
Warranty liabilities   9,295    19,797 
Inventory reserve   67,431    315,285 
Tax credits   66,716    61,832 
State tax   (18,793)   (18,863)
Lease Liability   

27,784

    - 
Right of Use Asset   

(25,543

)   - 
Deferred tax assets   484,047    630,953 
Less: valuation allowance   (484,047)   (630,953)
Deferred tax assets, net  $-   $- 

 

(1)

IRC Section 174 Research and Development (R&D) Expense Capitalization:

 

The Company is subject to U.S. research and experimental (“R&E”) expense rules under IRC Section 174. Prior to the enactment of the One, Big, Beautiful Bill Act (“OBBBA”) in 2025, R&E expenditures were required to be capitalized and amortized over five years for domestic research activities and fifteen years for foreign research activities, resulting in temporary differences and corresponding deferred tax assets.

 

The OBBBA, enacted in 2025, restores the immediate deductibility of domestic R&E expenditures for tax purposes beginning in tax years after enactment. As a result, domestic R&E costs incurred in 2025 and thereafter are fully expensed as incurred for tax purposes, eliminating the creation of new deferred tax assets related to domestic R&E capitalization. The requirement to capitalize and amortize foreign R&E expenditures remains unchanged.

 

Deferred tax assets related to previously capitalized domestic R&E expenditures continue to be amortized over their remaining recovery periods. The Company has evaluated the impact of this legislative change and adjusted its deferred tax balances accordingly. The enactment reduces future temporary differences associated with domestic R&E expenditures and may result in the reversal of existing deferred tax assets over time. The impact of the OBBBA on the Company’s deferred tax assets and income tax provision for the year ended December 31, 2025 was not material.

 

The enactment of the OBBBA is not expected to have a material impact on the Company’s effective tax rate due to the Company’s valuation allowance position.

SCHEDULE OF UNRECOGNIZED TAX BENEFITS

A reconciliation of the amount of unrecognized tax benefits is as follows:

 

   March 31,   December 31, 
   2026   2025 
         
Beginning balances  $6,627   $6,627 
Increases related to current year tax positions   -    - 
Ending balances  $6,627   $6,627 

The following table presents the aggregate changes in the balance of gross unrecognized tax benefits:

 

   2025   2024 
   Years ended 
   December 31, 
   2025   2024 
         
Beginning balances  $6,627   $6,627 
Increases related to current year tax positions   -    - 
Ending balances  $6,627   $6,627